Results for tag: "Agalsidase"

Agalsidase is a drug used to treat endocrine and metabolic disorders. It is a recombinant form of the enzyme alpha-galactosidase A, which is deficient in patients with Fabry disease. Agalsidase helps to reduce the accumulation of globotriaosylceramide (GL-3) in the body, which is the cause of the symptoms of Fabry disease. Agalsidase is administered intravenously and is available in two forms: agalsidase beta and agalsidase alfa. Agalsidase beta is approved for use in the United States, Europe, and other countries, while agalsidase alfa is approved in Europe and other countries. Agalsidase is used to treat the symptoms of Fabry disease, including pain, burning sensations, and tingling in the hands and feet. It can also help to reduce the risk of kidney failure, heart attack, and stroke. Agalsidase is also used to treat other endocrine and metabolic disorders, such as Gaucher disease and Pompe disease. The agalsidase market is highly competitive, with several companies offering the drug. Some of the major players in the market include Genzyme Corporation, Shire plc, Sanofi, and Pfizer Inc. Show Less Read more